BiotechTube
ForDoz Pharma

ForDoz Pharma

San Diego, United States· Est.
fordozpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

ForDoz Pharma is a private CDMO focused on addressing a critical gap in US-based manufacturing capacity for conventional and complex sterile injectables. Founded in 2014 and operational from a facility purchased in 2016, the company has built integrated capabilities to support the full product lifecycle, from development through commercial production. A key milestone was the 2024 FDA approval of its own generic Doxorubicin Hydrochloride Liposome Injection, demonstrating its technical prowess. The company's strategy leverages this proprietary manufacturing experience to attract CDMO clients seeking expertise in complex sterile drug products.

Oncology

Technology Platform

Proprietary sterile injectable platforms including conventional aqueous/lyophilized formulations, liposomal/nanoparticle drug delivery, microsphere/polymer controlled-release systems, and in situ depot formulations for long-acting injectables.

Opportunities

The company is positioned to capitalize on strong market trends, including the growing demand for complex injectables, a shortage of US-based sterile manufacturing capacity, and the industry's push for supply chain resilience.
Its recent FDA approval for a complex generic serves as a powerful validation to attract CDMO clients.

Risk Factors

Key risks include operational and regulatory risk associated with sterile manufacturing at a single facility, dependence on the success of client pipelines, and competition from larger, established CDMOs.
Execution risk on planned service expansions also presents a challenge.

Competitive Landscape

ForDoz competes in the sterile injectables CDMO space against large, diversified players like Catalent and Lonza, as well as other specialized injectable manufacturers. Its differentiation lies in its integrated end-to-end services for complex formulations and its US-based commercial-scale facility focused solely on sterile products.

More companies in Small Molecule Drugs →More companies in United States →